QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-upgrades-intra-cellular-therapies-to-overweight-raises-price-target-to-92

Piper Sandler analyst Charles Duncan upgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Neutral to Overweight and raises t...

 jp-morgan-maintains-overweight-on-intra-cellular-therapies-raises-price-target-to-81

JP Morgan analyst Jessica Fye maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the price target...

 rbc-capital-maintains-outperform-on-intra-cellular-therapies-lowers-price-target-to-106

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and lowers the price t...

 cantor-fitzgerald-maintains-overweight-on-intra-cellular-therapies-raises-price-target-to-130

Cantor Fitzgerald analyst Charles Duncan maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the p...

 ubs-maintains-neutral-on-intra-cellular-therapies-lowers-price-target-to-79

UBS analyst Ashwani Verma maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price target from $...

 goldman-sachs-maintains-neutral-on-intra-cellular-therapies-lowers-price-target-to-74

Goldman Sachs analyst Corinne Jenkins maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price t...

 needham-reiterates-buy-on-intra-cellular-therapies-maintains-100-price-target

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

 needham-reiterates-buy-on-intra-cellular-therapies-maintains-100-price-target

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

 intra-cellular-therapies-q2-2024-gaap-eps-016-beats-020-estimate-sales-161400m-beat-157880m-estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate...

 needham-maintains-buy-on-intra-cellular-therapies-raises-price-target-to-100

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $94 t...

 ubs-downgrades-intra-cellular-therapies-to-neutral-lowers-price-target-to-83

UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target ...

 rbc-capital-reiterates-outperform-on-intra-cellular-therapies-maintains-103-price-target

RBC Capital analyst Brian Abrahams reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and maintains $103 pr...

 chinas-bilibili-and-ollies-bargain-outlet-were-among-10-mid-cap-stocks-with-biggest-gains-in-the-last-week-june-16-june-22-2024-are-they-in-your-portfolio

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION